The U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc.'s (PFE) respiratory syncytial virus or RSV vaccine for older adults.
The Committee voted 7 to 4 on safety and 7 to 4 on effectiveness of RSV bivalent vaccine candidate PF-06928316 or RSVpreF, Pfizer said in a statement on Tuesday.
The vaccine candidate is currently under FDA review for the prevention of acute respiratory disease and lower respiratory tract disease caused by RSV in adults 60 years of age and older.
The FDA decision is expected by the Prescription Drug User Fee Act (PDUFA) goal date in May 2023.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.